1. Home
  2. SYRE

as of 08-04-2026 12:34pm EST

$101.67
+$6.74
+7.10%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Founded: 2013 Country:
United States
United States
Employees: N/A City: WALTHAM
Market Cap: 8.5B IPO Year: 2015
Target Price: $85.08 AVG Volume (30 days): 1.1M
Analyst Decision: Strong Buy Number of Analysts: 12
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.74 EPS Growth: -4861.62
52 Week Low/High: $14.51 - $105.09 Next Earning Date: 05-08-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: -128.28 Index: N/A
Free Cash Flow: -169252000.0 FCF Growth: N/A

AI-Powered SYRE Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 17 hours ago

AI Recommendation

hold
Model Accuracy: 76.42%
76.42%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of Spyre Therapeutics Inc. (SYRE)

Turtle Cameron

Chief Executive Officer

Sell
SYRE Jul 1, 2026

Avg Cost/Share

$88.16

Shares

15,000

Total Value

$1,315,346.42

Owned After

582,540

SEC Form 4

Form 1 Form 2
Burrows Scott L

Chief Financial Officer

Sell
SYRE Jul 1, 2026

Avg Cost/Share

$87.96

Shares

7,500

Total Value

$658,039.50

Owned After

99,719

Sloan Sheldon

Chief Medical Officer

Sell
SYRE Jul 1, 2026

Avg Cost/Share

$87.93

Shares

8,334

Total Value

$730,895.56

Owned After

0

SYRE Jun 23, 2026

Avg Cost/Share

$85.31

Shares

4,684,781

Total Value

$399,658,667.11

Owned After

0

SEC Form 4

SYRE Jun 22, 2026

Avg Cost/Share

$100.00

Shares

20,000

Total Value

$2,000,000.00

Owned After

68,606

SEC Form 4

Sloan Sheldon

Chief Medical Officer

Sell
SYRE Jun 3, 2026

Avg Cost/Share

$75.00

Shares

8,333

Total Value

$624,975.00

Owned After

0

SEC Form 4

Turtle Cameron

Chief Executive Officer

Sell
SYRE Jun 1, 2026

Avg Cost/Share

$70.43

Shares

15,000

Total Value

$1,056,486.02

Owned After

582,540

SEC Form 4

Form 1 Form 2
Burrows Scott L

Chief Financial Officer

Sell
SYRE Jun 1, 2026

Avg Cost/Share

$70.86

Shares

7,500

Total Value

$532,936.98

Owned After

99,719

SEC Form 4

Form 1 Form 2

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q1

Q1 2026 Earnings

8-K BUY

May 5, 2026 · 100% conf.

AI Prediction BUY

1D

+5.10%

$74.63

Act: +2.80%

5D

+12.40%

$79.82

Act: +5.68%

20D

+14.82%

$81.53

Act: +3.53%

Price: $71.01 Prob +5D: 100% AUC: 1.000
0001636282-26-000051

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.e618d017.1785154251.358092de

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

2026
Q1

Q1 2026 Earnings

8-K BUY

Apr 13, 2026 · 100% conf.

AI Prediction BUY

1D

+5.10%

$74.63

Act: +2.80%

5D

+12.40%

$79.82

Act: +5.68%

20D

+14.82%

$81.53

Act: +3.53%

Price: $71.01 Prob +5D: 100% AUC: 1.000
0001628280-26-024906

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.e618d017.1785154253.3580b6a5

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

2025
Q4

Q4 2025 Earnings

8-K SELL

Feb 19, 2026 · 100% conf.

AI Prediction SELL

1D

-0.27%

$37.71

Act: +14.28%

5D

-11.36%

$33.51

Act: +13.73%

20D

-14.16%

$32.45

Price: $37.81 Prob +5D: 0% AUC: 1.000
0001636282-26-000022

syre-20260219false000163628200016362822026-02-192026-02-19

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549


FORM 8-K


CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2026


SPYRE THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)


Delaware001-3772246-4312787 (State or Other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification No.)

221 Crescent Street Building 23 Suite 105

Waltham, MA 02453

(Address of Principal Executive Offices) (Zip Code)

Registrant’s Telephone Number, Including Area Code: 617 651-5940

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.0001 Par Value Per ShareSYRE The Nasdaq Stock Market LLC (Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition. On February 19, 2026, Spyre Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in this Item 2.02, including Exhibit 99.1 to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Exchange Act or under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits. (d)Exhibits

Exhibit Number Description

99.1Press release issued by Spyre Therapeutics, Inc. regarding its financial results for the fourth quarter and fiscal year ended December 31, 2025, dated February 19, 2026.

104Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SPYRE THERAPEUTICS, INC.

Date:February 19, 2026 By: /s/ Scott Burrows

Scott Burrows Chief Financial Officer

Share on Social Networks: